Maxhealth Medicine of Wuxi, China struck a deal with Switzerland’s Legacy Healthcare to commercialize Legacy’s CG 210 in Mainland China and Macao.
Maxhealth Medicine of Wuxi, China struck a deal with Switzerland’s Legacy Healthcare to commercialize Legacy’s CG 210 in Mainland China and Macao. CG210 is a botanical treatment for hair thinning and loss that has been shown to slow the rate of hair loss. Legacy develops innovative patentable botanical drugs in oncology supportive care and dermatology. Maxhealth, which commercializes drugs and medical devices in China, made an investment in Legacy, though financial details were not disclosed.
